Prospective trial schema and diagnostic groups. (A) Schema showing how patients were screened and selected for entry. Patients were placed into 1 of 3 groups based on their bone marrow findings. (B) Proportions of patients with and without mutations in each diagnostic group are shown after DNA sequencing 22 genes associated with myeloid neoplasms.